Abstract
Isocarboxazid, an iproniazid analog, showed better results in the treatment of 195 patients with depressive and acute schizophrenic reactions than were seen in varying numbers of patients on 7 other antidepressants, including 223 treated with iproniazid. With a median improvement time of 8 days, isocarboxazid alone equals or exceeds ECT in speed and effectiveness, and shows no major side effects. Isocarboxazid appears to have the strongest activation effect of any amine oxidase inhibitor, is easily managed in maintenance usage, and can be combined with other antidepressants or tranquilizers, at least one of the latter having been used with it in every one of the 195 patients in this series. It is quite effective in both acute schizophrenic and depressed patients, and the fact that these diagnoses constitute 83% of private psychiatric hospital admissions indicates the potential wide range of application of isocarboxazid. The mood-elevating effect of isocarboxazid correlates with the rise of norepinephrin...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
